Embed Size (px)
Citation preview
Factors That Increase the Risk of Myopathy in People Taking Statins
Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114:1315-1320
5) Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005; 95: 120–122.6) Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003; 289: 1681–1690.7) Lee AJ, Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother. 2001; 35: 26–31.8) Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, Marz W, Reckless JP, Stein EA. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003; 163: 553–564.9) Foody JM, Krumholz HM. Are statins indicated for the primary prevention of CAD in octogenarians? Antagonist viewpoint. Am J Geriatr Cardiol. 2003; 12: 357–360.24) Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, Keech A, Packard C, Simes J, Byington R, Furberg CD. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation. 2000; 102: 1893–1900.35) Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004; 109 (suppl I): III-50–III-57.
Relation between reduction in incidence of CV events and mean LDL cholesterol
reduction in major statin trials
Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114:1315-1320
Event rates plotted vs LDL cholesterol levels during
statin therapy in secondary-prevention studies
Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114:1315-1320
Coronary heart disease event rate in men and women as a function of HDL cholesterol levels in
the Framingham Heart Study
Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114:1315-1320
Cardiovascular event rates in statin trials as a function of the baseline level of HDL cholesterol in the placebo and active treatment arms (pravastatin 40 mg in
WOSCOPS)
Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114:1315-1320
Cardiovascular event rates in statin trials as a function of the baseline level of HDL
cholesterol in the placebo and active treatment arms (pravastatin 40 mg in the LIPID and CARE
trials)
Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114:1315-1320
Cardiovascular event rates in statin trials as a function of the baseline level of HDL cholesterol in the placebo and active
treatment arms (simvastatin 40 mg in the HPS)
Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114:1315-1320
